Search

Objective: To investigate the clinical characteristics and pregnancy outcomes of women with uterine rupture. Methods: This retrospective study analyzed clinical data from 43 women who experienced uterine rupture during delivery at the Affiliated Obstetrics and Gynaecology Hospital of Nanjing Medical University from December 2016 to December 2022. The participants were divided into scarred and non-scarred uterus groups based on their histories of uterine surgery. Additionally, the delivery outcomes of 20 women who underwent vaginal trial of labor was analyzed. Results: Of the 43 cases, 33 women involved a scarred uterus group, and 10 women involved a non-scarred uterus group. The non-scarred uterus group exhibited significantly higher intraoperative blood loss ≥ 1 000 mL（P ＜ 0.001）and cumulative blood loss ≥1 000 mL（P=0.003）compared to the scarred uterus group, along with a higher rate of blood transfusion（P=0.012). Among those 43 cases, 23 women underwent expected cesarean sections, while 20 opted for vaginal trial delivery. In the vaginal trial delivery patients, there was a notable increase in complete uterine ruptures（P=0.044）and rate of blood transfusion（P ＜ 0.001）in the group with uterine rupture detected during delivery（7 cases), compared with the group with uterine rupture detected after delivery（13 cases). Furthermore, the group with uterine rupture detected during delivery showed a higher incidence of abnormal amniotic fluid and fetal heart rate changes. Although these differences did not reach statistical significance（P ＞ 0.05), they still warrant significant clinical attention. Conclusion: Non-scarred uterus exhibit more bleeding when rupture occurs. Patients undergoing vaginal trial delivery who experience postpartum uterine rupture face more severe complications. It is essential to closely monitor amniotic fluid, fetal heart rate, and vital signs before and after delivery to promptly detect uterine rupture and reduce adverse pregnancy outcomes. [ABSTRACT FROM AUTHOR]

Copyright of Journal of New Medicine is the property of Sun Yat Sen University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the impacts of circular RNA lipoprotein receptor 6 （circLRP6） on cisplatin （CDDP） resistance to esophageal squamous cell carcinoma （ESCC） and its relevant potential molecular mechanism. Methods CDDP‐resistant cell lines of KYSE30（ KYSE30/CDDP‐R） were established and divided into a control group, si‐NC group, si‐circLRP6 group, si‐circLRP6 plus anti‐NC group, and si‐circLRP6 plus anti‐miR‐ 125a‐5p group. The expression levels of circLRP6, miR‐125a‐5p and myeloid leukemia‐1 （MCL‐1） in tissues/cells were detected by RT‐qPCR and Western blot. CCK‐8 assay was applied to detect the CDDP sensitivity of KYSE30/CDDP‐R cells, so was flow cytometry to detect apoptosis. Results mRNA levels of circLRP6 and MCL‐1 were increased, while level of miR‐125a‐5p was decreased in ESCC cancer tissues/cells and CDDP‐resistant cancer tissues （P < 0.001）. CircLRP6 silencing was able to up‐regulate miR‐125a‐5p, inhibit the expression of MCL‐1, enhance the sensitivity of CDDP‐resistant ESCC cells to CDDP in vitro and in vivo, and promote the apoptosis of CDDP‐resistant ESCC cells. Inhibition of miR‐125a‐5p weakened the effects of circLRP6 silencing on CDDP resistance and apoptosis in CDDP‐resistant ESCC cells （P < 0.05）. circLRP6 could target and negatively regulate the expression of miR‐125a‐5p, and MCL‐1 was the target of miR‐125a‐5p. Conclusion CircLRP6 silencing may enhance the sensitivity of CDDP‐resistant ESCC cells to CDDP through the miR‐125a‐5p/MCL‐1 axis. [ABSTRACT FROM AUTHOR]

Copyright of Tobacco Science & Technology is the property of Tobacco Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

NOP56 is a nucleolar protein that closely relates to the expression oncogene. In this paper， the differential expression gene analysis of the data from online database revealed that NOP56 is overexpressed in breast cancer tissues. The expression of NOP56 was used as a phenotype to analyze the difference between different phenotypes and clinical prognosis. Results showed that the high expression of NOP56 was closely related to the poor clinical pathological parameters and prognosis of breast cancer. The protein interaction network of NOP56 was obtained by differential gene enrichment analysis，and the semantic similarity of co-expressed genes was calculated. Finally，the clinically targeted drug actinomycin D (dactinomycin) of NOP56 and its co-expressed genes were obtained from an online database. These results provide potential new predictive indicators for breast cancer prevention and treatment， improve the molecular mechanism of clinical targeted drug use， and provide evidence and clues for the clinical use of targeted drugs. [ABSTRACT FROM AUTHOR]

OBJECTIVE ： To investigate the compatible stability of homebred voriconazole injection and fructose injection with the ingredients of hydroxypropyl-p-cyclodextrin. METHODS ： To observe the changes of characters of solution, the number of insoluble particle and pH within 5 h in voriconazole injection that was diluted by fructose injection, and the internal standard method of high performance liquid chromatography was established to determine its content. RESULTS ： After the compatibility of voriconazole injection and fructose injection, there were no obvious changes in the characters of solution, pH within 5 h and voriconazole content, and the number of insoluble particle had met the specification of Pharmacopoeia of the Peopled Republic. CONCLUSIONS： The compatibility of homebred voriconazole injection and fructose injection is stable within 5 h. [ABSTRACT FROM AUTHOR]

Objective To observe the expression of fibroblast growth factor 4 (FGF4) in the lung cancer tissues, and to discuss the effects of FGF4 on the proliferation and metastasis of lung cancer cells. Methods We selected 40 cases of lung cancer tissues and their corresponding paraeaneerous tissues, human lung fibroblast cell line HFL1 , human low metastatic lung cancer cell line NL9980, and human high metastatic lung cancer cell line A549. The mRNA expression of FGF4 in the tissues and cells was detected by RT-PGR, and the protein expression of FGF4 in the cells was detected by Western blotting. N1L9980 cells were transfected with Lipo2000 to construct stable cell line NL9980-FGF4-OE with over-expression of FGF4. The negative controls were NL9980 cell line only transfected with pCDNA3. 1 , that was NL9980-NC. A549 cells were transfected with Lipo2000 to construct the stable cell line A549-FGF4-si with knockout of FGF4. The negative control was A549 cell line transfected with pCDNA3. 1 , namely A549-NC. Meanwhile, the proliferation ability of NL9980-NC, NL9980-FGF4-oe, A549-NC, and A549-FGF4-si cells was detected by MTT assay, and the cell migration ability was detected by Scratch test. Results The mRNA expression of FGF4 in the lung cancer tissues was higher than that of the adjacent tissues (P < 0. 05). W hat ’ s more, the mRNA and protein expression levels of FGF4 was in the following order; A549 > NL9980 > HFL1 (all P<0.05). The proliferation capacity of NL9980-FGF4-oe cells was higher than that of NL9980-NC, at the same time, the proliferation capacity of A549-FGF4-si cells was lower than that of A549-NC cells (both P < 0. 05). The migration distance of NL9980-FGF4-oe cells was greater than that of NL9980-NC cells, meanwhile, the migration distance of A549-FGF4-si cells was shorter than A549-NC (both P < 0.05). Conclusion FGF4 is highly expressed in the lung cancer tissues, and its over-expression can promote the proliferation and metastasis of lung cancer cells. [ABSTRACT FROM AUTHOR]